0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover1994.84%IV-84.84%PremiumOct 11, 2024Expiry Date4.59Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6061Delta0.0816Gamma0.99Leverage Ratio-1.3240Theta-0.0002Rho-0.60Eff Leverage0.0009Vega
Inovio Pharmaceuticals Stock Discussion
On Friday, the fear of human-to-human spread grew ever so slightly: The CDC confirmed that four health-care workers in Missouri had fallen sick after caring for a patient who was infected with bird flu.
https://www.msn.com/en-us/health/other/bird-flu-pandemic-fears-skyrocket-as-us-identifies-first-cases-of-possible-human-to-human-transmission/ar-AA1rwhf5?ocid=BingNewsSerp
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet